Shares of Autolus Therapeutics PLC Sponsored ADR (NASDAQ:AUTL - Get Free Report) were down 5.1% on Tuesday . The stock traded as low as $2.55 and last traded at $2.52. Approximately 266,099 shares were traded during mid-day trading, a decline of 83% from the average daily volume of 1,563,189 shares. The stock had previously closed at $2.65.
Analysts Set New Price Targets
A number of equities analysts have recently commented on the stock. Truist Financial cut their target price on shares of Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating on the stock in a report on Tuesday, April 1st. Wells Fargo & Company lowered their price objective on shares of Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research report on Friday, March 21st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, June 12th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of "Buy" and a consensus price target of $9.32.
Check Out Our Latest Analysis on Autolus Therapeutics
Autolus Therapeutics Stock Performance
The company has a market cap of $641.40 million, a PE ratio of -2.74 and a beta of 1.81. The stock's 50-day simple moving average is $2.04 and its 200 day simple moving average is $1.89.
Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The business had revenue of $8.98 million for the quarter, compared to the consensus estimate of $1.59 million. On average, sell-side analysts predict that Autolus Therapeutics PLC Sponsored ADR will post -0.94 EPS for the current fiscal year.
Hedge Funds Weigh In On Autolus Therapeutics
A number of large investors have recently bought and sold shares of AUTL. EntryPoint Capital LLC purchased a new position in Autolus Therapeutics during the 4th quarter worth $450,000. Mitsubishi UFJ Asset Management Co. Ltd. grew its stake in shares of Autolus Therapeutics by 21.2% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 82,411 shares of the company's stock worth $194,000 after purchasing an additional 14,432 shares during the period. BIT Capital GmbH grew its stake in shares of Autolus Therapeutics by 147.0% during the 4th quarter. BIT Capital GmbH now owns 636,979 shares of the company's stock worth $1,497,000 after purchasing an additional 379,050 shares during the period. Wellington Management Group LLP grew its stake in shares of Autolus Therapeutics by 4.6% during the 4th quarter. Wellington Management Group LLP now owns 25,345,680 shares of the company's stock worth $59,562,000 after purchasing an additional 1,125,454 shares during the period. Finally, HighPoint Advisor Group LLC acquired a new position in shares of Autolus Therapeutics during the 4th quarter worth $185,000. Hedge funds and other institutional investors own 72.83% of the company's stock.
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Featured Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.